fenglizhao@ojlab.ac.cn
September 2009 – July 2016
Doctoral Degree: China Agricultural University, Major in Physiology
December 2016 – December 2021
Postdoctor, City of Hope National Medical Center,USA
December 2021 - May 2023
Associate Researcher, City of Hope National Medical Center,USA
August 2023 – Present
Professor, Oujiang Lab
December 2016 – December 2021
Postdoctor, City of Hope National Medical Center,USA
December 2021 - May 2023
Associate Researcher, City of Hope National Medical Center,USA
August 2023 – Present
Professor, Oujiang Lab
Overview of Academic Research
Our research group is dedicated to addressing major diseases, including neurogenetic rare diseases, neurodegenerative disorders, and brain tumors. We focus on overcoming key challenges in the clinical translation of stem cell therapies by developing innovative iPSC-based treatments through the deep integration of cutting-edge technologies like artificial intelligence.The primary research thrusts encompass:
1. The development of highly efficient differentiation methods for iPSCs across diverse cell types, such as neural stem cells and oligodendrocyte progenitor cells.
2. The mechanism and therapy for demyelinating diseases, such as multiple sclerosis and leukodystrophies.
3. The engineering and application of various brain organoids, myelinating organoids, and brain tumor organoids.
4. The disease mechanism and therapeutic development of newly identified brain developmental disorders.
5. Exploring and applying artificial intelligence to advance biological research .
1. Selected into Wenzhou “Ouyue Yingcai”, 2024
2. Treatment of Canavan disease.USA, WO2022076206A1, Shi Y., Feng L., Chao J., Sun G..
3. Research on Gene- and Cell Therapeutic Strategies for Neurodevelopmental Disorders Caused by ZNF526 Deficiency. 2024.12-2026.11
4. California Institute for Regenerative Medicine (CIRM, TRAN1-08525), USA, Preclinical research (GLP) based on iPSC stem cell therapy for Canavan disease, $7.37 million USD, one of the principal investigators.
5. NIH (U01-NS122101), USA, Preclinical research and Phase I clinical study preparation for iPSC stem cell therapy for Canavan disease, $7.8 million USD, significant participant.
1. Feng L., Chao J., Ye P., Luong Q., … Liu Z., Hu W., Shi Y. (2023). Developing Hypoimmunogenic Human iPSC-Derived Oligodendrocyte Progenitor Cells as an Off-The-Shelf Cell Therapy for Myelin Disorders. Advanced Science, 2206910. Doi: 10.1002/advs.202206910. 第一作者
2. Feng L.*, Chao J.*, Tian E.*, Li L.*, Ye P., … Goldman SA., Matalon R., Shi Y. (2020). Cell-Based Therapy for Canavan Disease Using Human iPSC-Derived NPCs and OPCs. Advanced Science, 7(23):2002155. Doi: 10.1002/advs.202002155. 共同第一作者
3. Feng L., Chao J., ZhangM., Pacquing E., Hu W., Shi Y. (2023). Developing a human iPSC-derived three-dimensional myelin spheroid platform for modeling myelin diseases, iScience, 26(11): 108037. 第一作者
4. Li L., Tian E., …Ye P., Feng L., Li X… Shi Y. (2018). Astrocytes Impair Oligodendrocyte Progenitor Proliferation and Myelination in an hiPSC Model of Alexander Disease. Cell Stem Cell 23(2):239-251. Doi: 10.1016/j.stem.2018.07.009. 共同作者
5. Liu Z., Chao J., …Tian E, Feng L., Hayk D… Shi Y. (2023). Astrocytic response mediated by the CLU risk allele inhibits OPC proliferation and myelination in a human iPSC model. Cell Reports 42(8):112841. Doi: 10.1016/j.celrep.2023.112841. 共同作者
